Evolocumab before percutaneous coronary intervention for acute myocardial infarction: Design of the AMUNDSEN trial
Authors' conclusion
The AMUNDSEN trial will provide critical insights into the potential benefits of early PCSK9 inhibition in high-risk MI patients undergoing PCI.
Study context
- Population
- High-risk acute MI patients (STEMI undergoing primary percutaneous coronary intervention (PCI) or NSTEMI with indication for PCI) with ≥1 high-risk clinical characteristicenrolment complete
- Participants
- 2,166 patients
- Comparison
- Immediate evolocumab before PCI plus standard care vs standard care alone
- Primary endpoint
- Both ≥50% reduction in LDL-C from baseline and LDL-C <55 mg/dL
- Follow-up
- 12 months
Methodological detailsAMUNDSEN, international, phase IV, PROBE (prospective randomised open, blinded endpoint), Main clinical objective: composite of all-cause death or unplanned hospitalisation for a cardiovascular (CV) reason at 12 months
- AMUNDSEN
- International
- Phase IV
- PROBE (prospective randomised open, blinded endpoint)
- Main clinical objective: composite of all-cause death or unplanned hospitalisation for a CV reason at 12 months
Primary result
As reported in the abstract
- No results reported; lipid and clinical follow-up ongoing
Original publication
Evolocumab before percutaneous coronary intervention for acute myocardial infarction: Design of the AMUNDSEN trial. Am Heart J. Published 3 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →